FDA approvals for new biosimilars like Starjemza and Hadlima enhance treatment options, addressing urgent needs for ...

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

A new State of Drug Access report shows that more than 40% of people living in the US could not afford their prescribed drugs ...

From five years of sales declines to nine consecutive quarters of growth, it’s hard to deny that Teva’s revamp under CEO ...

Prescription drugs prices have rapidly increased, but opting for generic medications and incorporating lifestyle changes are some ways to cut costs.

Samsung may separate its foundry business from its semiconductor division. This move addresses conflict of interest concerns.

Some Michigan hospitals are marking up prices by thousands of dollars above what they pay manufacturers for certain prescription drugs, according to a new report from the Michigan Health Purchasers ...

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Starjemza, ...

The designation allows pharmacists to substitute it for Humira without prescriber approval (per state law), which expands ...

AbbVie ABBV stock has declined 12.6% in the past three months. The stock is also trading below its 50-day and 200-day moving ...

Retinal drugs market growth driven by aging population, rising AMD prevalence, and advances in ophthalmic drug delivery and retinal disease treatment innovation.